Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung Cancer Patients: A Retrospective Study.

[1]  N. Chaput,et al.  The use of immunotherapy in older patients with advanced non-small cell lung cancer. , 2022, Cancer Treatment Reviews.

[2]  R. Simes,et al.  Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. , 2022, Lung cancer.

[3]  M. Kriegsmann,et al.  Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer , 2021, Frontiers in Oncology.

[4]  S. Mohile,et al.  Understanding Treatment Tolerability in Older Adults With Cancer. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Kanesvaran,et al.  Immunotherapy in Older Adults With Cancer. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Christopoulos,et al.  Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer , 2021, International journal of molecular sciences.

[7]  H. Cohen,et al.  Predictors of Unplanned Hospitalizations Among Older Adults Receiving Cancer Chemotherapy , 2021, JCO oncology practice.

[8]  E. Felip,et al.  Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  P. Lorigan,et al.  A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study , 2021, ESMO open.

[10]  S. Fröhling,et al.  A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma , 2021, Oncoimmunology.

[11]  A. Stenzinger,et al.  Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA , 2020, EBioMedicine.

[12]  C. Schumann,et al.  Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). , 2020, Lung cancer.

[13]  H. Cohen,et al.  Older adult participation in cancer clinical trials: A systematic review of barriers and interventions , 2020, CA: a cancer journal for clinicians.

[14]  P. Christopoulos,et al.  Breaking Bottlenecks for the TCR Therapy of Cancer , 2020, Cells.

[15]  M. Kriegsmann,et al.  Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing. , 2020, Lung cancer.

[16]  A. Tafreshi,et al.  A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. , 2020, Journal of Thoracic Oncology.

[17]  A. Ardizzoni,et al.  ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data. , 2020, Lung cancer.

[18]  A. Stenzinger,et al.  Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial , 2020, Trials.

[19]  S. Fröhling,et al.  Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. , 2020, Lung cancer.

[20]  G. Galli,et al.  Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. , 2019, Lung cancer.

[21]  Olaf Neumann,et al.  Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases , 2019, International journal of cancer.

[22]  A. Stenzinger,et al.  Defining molecular risk in ALK+ NSCLC , 2019, Oncotarget.

[23]  L. Heinzerling,et al.  Senescence markers: Predictive for response to checkpoint inhibitors , 2018, International journal of cancer.

[24]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[25]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[26]  T. Mok,et al.  Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. , 2018, Journal of Clinical Oncology.

[27]  Y. Shentu,et al.  Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). , 2018 .

[28]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[29]  P. Brown,et al.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.

[30]  David Smith,et al.  Frailty as determined by a comprehensive geriatric assessment‐derived deficit‐accumulation index in older patients with cancer who receive chemotherapy , 2016, Cancer.

[31]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[32]  Edward S. Kim,et al.  Clinicopathologic Features of Advanced Squamous NSCLC. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  G. Lyman,et al.  Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.

[34]  Supriya G Mohile,et al.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Taofeek K Owonikoko,et al.  Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Creditor.  Hazards of Hospitalization of the Elderly , 1993, Annals of Internal Medicine.